Pfizer reveals the discontinuation of PF-08046044.

Studies presented at ASH show this to be true only up to a point.

Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.

Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.

The company might have blown Enliven out of the water.

Of 15 treatment-emergent adverse events, only one was deemed related to therapy.